UK MHRA authorises BridgeBio's acoramidis for ATTR-CM

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma's acoramidis under the name Beyonttra, for treating wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Acoramidis is an orally administered selective small molecule that stabilises transthyretin (TTR) by more than 90%.
This authorisation was supported by the outcomes from the pivotal ATTRibute-CM Phase III trial, which demonstrated cardiovascular benefits.
In the trial, the therapy's safety and efficacy were assessed in 632 symptomatic ATTR-CM subjects, and they were given either the therapy or a placebo for a 30-month period.
The primary clinical endpoints were met at month 30, showing a decrease in cardiovascular-related hospitalisations, preservation of functional capacity, improved survival and quality of life for subjects.
The therapy received the US Food and Drug Administration's (FDA) approval under the name Attruby in November 2024, and as Beyonttra by the European Commission (EC) in February 2025.
It was also approved in Japan by the Ministry of Health, Labour, and Welfare in March 2025.
In the UK, Bayer will manage all commercial activities for the therapy.
In March 2024, the company and Bayer entered a partnership granting the latter exclusive rights to commercialise the therapy in Europe.
According to the licencing agreement, BridgeBio will obtain tiered royalties starting in the low-thirties percent on UK sales after commercialisation efforts commence.
ATTR-CM is a fatal condition that causes heart failure due to restrictive cardiomyopathy.
BridgeBio Cardiorenal chief medical officer and president Jonathan Fox stated: 'We are proud to add another approval for acoramidis and thrilled that patients in the UK will now have access to Beyonttra since they are in great need of new disease-modifying treatments for their condition.
'We look forward to extending our collaboration with our European partner, Bayer, to serve ATTR-CM patients across the UK and the rest of Europe, and will continue to work towards reaching patients in as many regions as possible around the world."
"UK MHRA authorises BridgeBio's acoramidis for ATTR-CM" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

a day ago

• Yahoo

Crop science in the spotlight as new trials site hosts open day

Crop trials showcasing wheat varieties and the latest disease control strategies will be shown to farmers at an open day in west Norfolk. The Bayer Field Day in Walpole on July 3 takes place at the company's new Norfolk demonstration site, inviting farmers, agronomists and industry stakeholders to "explore the latest advancements in crop science and sustainable farming practices". Trial plots will compare wheat varieties from the Recommended List (RL) and RL candidates, giving the opportunity to assess how they perform under real-world conditions. Meanwhile, fungicide trials will highlight both current and future chemistry aimed at tackling yield-damaging infections like septoria, yellow rust, and brown rust. Another key topic is grass-weed control, discussing strategies for slowing the progress of resistance, while optimising efficacy. In addition to the demonstrations, there will be static displays and a chance to speak to Bayer experts. The event takes place from 10am on July 3 at Pear Tree Farm, Mill Road, Walpole, near King's Lynn, PE14 7QJ. The last tour will be at 3pm. Food and refreshments will be available. For further information visit

Yahoo

a day ago

• Yahoo

Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

News24

3 days ago

• News24

Liverpool bank on ‘world-class' Wirtz after record deal

The golden boy of German football is set to become the new prince of the Premier League after Florian Wirtz joined Liverpool from Bayer Leverkusen for a club-record fee. Fresh from winning a 20th English top-flight title, Arne Slot's Reds have broken the bank to land a rising star already labelled as one of the world's best by former Reds midfielder and Wirtz's former coach Xabi Alonso. British media reported on Friday that the Premier League champions had agreed a deal worth up to £116 million ($157 million) to secure the services of the attacking midfielder. German reports claim the fee is even higher, starting at 130 million euros (£111 million, $149 million) and increasing with add-ons to 150 million euros. Wirtz's abundant potential as a teenager sparked a row between his hometown club Cologne and Leverkusen five years ago when Leverkusen, who are backed by pharmaceutical giants Bayer, swooped to sign him at 17. Cologne argued that a gentleman's agreement not to poach youth team players had been violated, but Leverkusen said Wirtz was a first-team signing, and within months, he had made his Bundesliga debut. His rise was interrupted by a cruciate knee ligament injury in March 2022 that forced him to miss the next 10 months. By the time he returned, Alonso had been installed as Leverkusen boss, and together, they would spearhead the club's greatest days. Leverkusen ended Bayern Munich's dominance of the Bundesliga in stunning fashion, romping to the title and the German Cup without losing a single match in the 2023/24 season. Officially a Red ✍️ — Liverpool FC (@LFC) June 20, 2025 Wirtz netted his first career hat-trick on the day the title was sealed against Werder Bremen, on his way to being crowned Bundesliga player of the year. 'Flo is one of the top players in the world; he's world-class,' said Real Madrid coach Alonso, who compared his protege to Lionel Messi in terms of his understanding of the game. 'Why is Messi so good? Because he knows how and when to play simple passes. Messi says: 'You're in a better position? Here, there you have the ball',' added Alonso, a hero of Liverpool's 2005 Champions League triumph. 'It's not always about making the most brilliant move, but the best and smartest. Florian can do that. That's why he's so good.' Both star player and coach committed to staying with the Leverkusen project for another 12 months, but defeat in the Europa League final to Atalanta to round off the 2023/24 campaign was a sign of things to come. Bayern restored their grip on the German game last season but could not convince Wirtz to follow the lead of many others in joining from their Bundesliga rivals. Instead, he made it clear that his preference was to move to the Premier League champions and to have the chance to add his name to Liverpool's cast of legends. 'I'm really excited to have a new adventure in front of me. This was also a big point of my thoughts: that I want to have something completely new, to go out of the Bundesliga and to join the Premier League,' said Wirtz. 'I spoke also with some players who played there and they told me that it's perfect for me and every pitch is perfect, you can enjoy every game. I'm really looking forward to playing my first game.' Despite 57 goals and 65 assists in 197 games for Leverkusen, Wirtz will begin life at Anfield in the shadow of Mohamed Salah. But the Reds are banking on Wirtz's creativity to help maintain the 32-year-old's prolific goalscoring numbers and ease the burden of carrying the Liverpool attack. The club's previous record signing, £85 million recruit Darwin Nunez, has failed to deliver and could be sold to help recoup some of their major outlay on new faces. Liverpool will hope Wirtz can handle the pressure of his price tag and the physicality of the Premier League to ensure there is no second season slump under Slot.